Noxopharm Limited (ASX: NOX)
Health Care · Biotechnology · AU
AU$0.09
+17.50% today · -10.5% 1Y
Noxopharm Limited (ASX: NOX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $20.70M and employs 8 people.
Over the last twelve months the share price has lost 10.5%, trading between 0.05 and 0.12.
Tweenvest scores Noxopharm Limited across four factors: quality 13/100, value 60/100. Its strongest factor is value.
NOX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $20.70M
- Revenue (TTM)
- $2.26M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.00
- 52-week high
- AU$0.12
- 52-week low
- AU$0.05
- Avg volume (3M)
- —
- Shares outstanding
- 307.24M
- Employees
- 8
- Next earnings
- —
About Noxopharm Limited
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
- ISIN
- AU000000NOX9
- Founded
- 2015
- Listed since
- Aug 9, 2016
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.16 | -0.14% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.53 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $549.99 | +0.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €873.60 | +1.09% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.30 | +1.74% |
Figures last refreshed Aug 18, 2026.